Revolution in Prostate Cancer Diagnosis: Artificial Intelligence Leads the New Era of Fusion Biopsies
Artificial intelligence is making a dynamic entry into urology, offering new possibilities for the early and accurate diagnosis of prostate cancer.
For the first time in Southeastern Europe, this technology is being utilized in fusion prostate biopsy under the guidance of Dr. Andreas Andreou, Director of the 2nd Department of Urology at Interbalkan Medical Center Thessaloniki, opening a new path toward personalized patient care.
Multiparametric magnetic resonance imaging (MRI) of the prostate is currently the primary tool for identifying suspicious areas. However, interpreting these images requires a high level of expertise and experience. Artificial intelligence serves as a valuable partner to the urologist and radiologist, analyzing the images and identifying with high accuracy lesions that may correspond to clinically significant cancer.
During a fusion biopsy, MRI images are fused with ultrasound images in real time. With the assistance of artificial intelligence, this fusion is performed with exceptional precision, ensuring that the biopsy needle is directed precisely to the area of interest. This increases the likelihood of detecting aggressive forms of cancer while simultaneously reducing the need for repeat procedures.
The benefits for patients are numerous.
More accurate diagnosis enables timely treatment decisions and helps avoid both overtreatment and undertreatment. In addition, the data collected during the procedure provide valuable information for planning the next stage of treatment, whether this involves active surveillance, surgery, or another targeted therapy.
The integration of artificial intelligence into prostate biopsy does not replace medical judgment. On the contrary, it enhances the capabilities of the medical team, providing an additional level of accuracy and safety. This technology is a clear example of how innovation can translate into meaningful benefits for patients.
Its first application in Southeastern Europe by Dr. Andreas Andreou and the 2nd Department of Urology at Interbalkan Medical Center Thessaloniki marks an important milestone for the region. At the same time, it highlights the leading role of Greek medicine in adopting advanced technologies that improve the diagnosis and treatment of prostate cancer.
As artificial intelligence continues to evolve, it is expected to play an increasingly important role in medicine, offering patients more personalized, safer, and more effective care.
Author
